OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+75.06%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$495M
AUM Growth
+$495M
(+31%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
3.86%
Top 10 Holdings %
Top 10 Hldgs %
52.26%
Holding
59
New
16
Increased
13
Reduced
8
Closed
11
Top Buys
| 1 |
Celldex Therapeutics
CLDX
|
$13.9M |
| 2 |
Fortress Biotech
FBIO
|
$10.3M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$8.78M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$8.36M |
| 5 |
Ocular Therapeutix
OCUL
|
$7.18M |
Top Sells
| 1 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
$36.8M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
$5.63M |
| 3 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$4.83M |
| 4 |
Zymeworks
ZYME
|
$4.72M |
| 5 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
$4.66M |
Sector Composition
| 1 | Healthcare | 91.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RDUS
51
DELISTED
Radius Health, Inc.
RDUS
| – | – | -167,000 | Closed | -$2.17M |
|
|
FLXN
52
DELISTED
Flexion Therapeutics, Inc.
FLXN
| – | – | -281,600 | Closed | -$2.22M |
|
|
KDMN
53
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – | -1,152,250 | Closed | -$4.83M |
|
|
FTSV
54
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| – | – | -385,500 | Closed | -$36.8M |
|
55
Acadia Pharmaceuticals
ACAD
$4.38B
| – | – | -1,500 | Closed | -$63K |
|
56
Minerva Neurosciences
NERV
$16.5M
| – | – | -450,100 | Closed | -$2.71M |
|
57
Cartesian Therapeutics
RNAC
$261M
| – | – | -390,000 | Closed | -$940K |
|
58
Verastem
VSTM
$569M
| – | – | -1,463,900 | Closed | -$3.87M |
|